API | custirsen

custirsen Report issue

Biologics Nucleic acid Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Custirsen, aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving over all survival. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

custirsen

custirsen sodium

More Chemistry

Pharmacology

Mechanism of Action:
- Estrogen receptor (Homo sapiens) ^UniProt
- Estrogen receptor beta (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

custirsen | custirsen sodium | isis-112989 | ogx-011

Organizations (13)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (2)

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (10)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Heart Diseases (Phase 1)

Kidney Neoplasms (Phase 1)

Lung Neoplasms (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 3)

Urinary Bladder Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue